Generic Cambia Availability

Cambia is a brand name of diclofenac, approved by the FDA in the following formulation(s):

CAMBIA (diclofenac potassium - for solution;oral)

  • Manufacturer: DEPOMED INC
    Approval date: June 17, 2009
    Strength(s): 50MG [RLD]

Has a generic version of Cambia been approved?

No. There is currently no therapeutically equivalent version of Cambia available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cambia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical compositions based on Diclofenae
    Patent 6,974,595
    Issued: December 13, 2005
    Inventor(s): Reiner; Alberto & Reiner; Giorgio
    Assignee(s): ProEthic Pharmaceuticals, Inc.
    New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.
    Patent expiration dates:
    • May 15, 2017
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  • Pharmaceutical compositions and methods of treatment based on diclofenac
    Patent 7,482,377
    Issued: January 27, 2009
    Inventor(s): Reiner; Alberto & Reiner; Giorgio
    Assignee(s): Kowa Pharmaceuticals America, Inc.
    New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.
    Patent expiration dates:
    • May 15, 2017
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Diclofenac formulations and methods of use
    Patent 7,759,394
    Issued: July 20, 2010
    Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
    Assignee(s): APR Applied Pharma Research SA
    Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Patent expiration dates:
    • June 16, 2026
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Diclofenac formulations and methods of use
    Patent 8,097,651
    Issued: January 17, 2012
    Inventor(s): Reiner; Giorgio & Reiner; Alberto & Meyer; Andreas
    Assignee(s): APR Applied Pharma Research s.a.
    Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Patent expiration dates:
    • June 16, 2026
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)